| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 1g | |||
| Other Sizes |
| Targets |
BRD4097 targets HDACs, especially HDAC1, 2, and 3. It is an inhibitor that binds to the active sites of these enzymes through metal chelation and spatial rejection mechanisms. By inhibiting HDAC activity, the compound alters gene expression and chromatin structure. This inhibition has been shown to have various biological effects, including protecting β-cells and improving cognitive function.
|
|---|---|
| ln Vitro |
In vitro, BRD4097 has been shown to inhibit HDAC activity. It is used as a negative control in HDAC1/2/3/8 assays. The compound's ability to inhibit HDACs has been confirmed in cell-based assays.
|
| ln Vivo |
In vivo, BRD4097 has been shown to protect β-cells and improve insulin resistance. It also helps promote cognitive function and enhance learning and memory formation. These effects are consistent with its mechanism of action as an HDAC inhibitor.
|
| Enzyme Assay |
In vitro enzyme or receptor binding (non-cell) assays for BRD4097 involve measuring its direct inhibition of HDAC enzymatic activity. The assay uses a purified recombinant HDAC enzyme (e.g., HDAC1, 2, or 3) and a fluorogenic peptide substrate. The deacetylation of the substrate releases a fluorescent product. The compound is incubated with the enzyme and substrate, and the decrease in fluorescence is measured to determine the IC50.
|
| Cell Assay |
In vitro cell-based assays for BRD4097 are performed using various cell lines. Cells are treated with the compound, and the acetylation of histones is assessed by Western blotting. Cell viability and proliferation are measured using standard assays. The compound's effects on β-cell function can be assessed by measuring insulin secretion.
|
| Animal Protocol |
In vivo animal experiments for BRD4097 are conducted using mouse models of diabetes and cognitive disorders. The compound is administered, and its effects on blood glucose, insulin sensitivity, and cognitive function are assessed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic (PK) properties of BRD4097 have been characterized to support its use as a research tool. The compound has a molecular weight of 283.33 and a formula of C₁₆H₁₇N₃O₂. It is soluble in DMSO. Specific PK parameters, such as half-life and bioavailability, are determined in preclinical studies via LC-MS/MS analysis of plasma samples.
|
| Toxicity/Toxicokinetics |
Toxicology (toxicology) data for BRD4097 are typical of a research compound. It is generally well-tolerated at effective doses. The safety profile is being evaluated in the context of its use as a research tool to study HDAC biology.
|
| Additional Infomation |
Other information: BRD4097 is a research compound used to study HDACs, diabetes, and cognitive function. It is available from chemical suppliers for preclinical research purposes.
|
| Molecular Formula |
C16H17N3O2
|
|---|---|
| Molecular Weight |
283.33
|
| Exact Mass |
283.132
|
| CAS # |
1550053-19-4
|
| PubChem CID |
73055061
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
1.9
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
21
|
| Complexity |
378
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=CC(=C(C=C1)NC(=O)C2=CC=C(C=C2)NC(=O)C)N
|
| InChi Key |
HRMBUIZWNJTBSE-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H17N3O2/c1-10-3-8-15(14(17)9-10)19-16(21)12-4-6-13(7-5-12)18-11(2)20/h3-9H,17H2,1-2H3,(H,18,20)(H,19,21)
|
| Chemical Name |
4-acetamido-N-(2-amino-4-methylphenyl)benzamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5295 mL | 17.6473 mL | 35.2945 mL | |
| 5 mM | 0.7059 mL | 3.5295 mL | 7.0589 mL | |
| 10 mM | 0.3529 mL | 1.7647 mL | 3.5295 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
